Results 51 to 60 of about 3,273 (206)
Cancer Medicine, Volume 15, Issue 4, April 2026.During the study period, 709 patients were treated with immune checkpoint inhibitors (ICIs) at our institution. Endocrine immune‐related adverse events (irAEs) were diagnosed in 84 patients, all of whom were evaluated and managed by endocrinologists; the most common irAEs were thyroid dysfunction (64.3%) and adrenal insufficiency (42.9%), followed by ...
Kota Nishihama +10 more
wiley +1 more source
, 2008 We sought to compare the treatment modalities of alendronate, alfacalcidol, and alendronate combined with alfacalcidol in renal transplant recipients with low bone mineral density.
Trabulus, S. +4 more
core +1 more source
Burosumab in Unidentifiable Tumor‐Induced Osteomalacia
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Tumor‐induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti‐FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia.
Yi Shan Der +5 more
wiley +1 more source
Otsenka riska padeniy zhenshchin s postmenopauzal'nymosteoporozom, poluchayushchikh al'fakal'tsidol
Остеопороз и остеопатии, 2010 The study objective: to assess the influence of alfacalcidol treatment on risk of falling in real clinical practice. Methods. Prospective cohort study included 46 postmenopausal women aged from 52 to 78, who had high risk of falling, low bone mineral ...
M. V. Strunina +3 more
doaj +1 more source
Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.Background Denys‐Drash syndrome (DDS) is a rare genetic disorder characterized by mutations in the Wilms tumor suppressor gene (WT1), leading to a triad of conditions including nephrotic syndrome progressing to end‐stage renal disease (ESRD), Wilms tumor, and ambiguous genitalia.
Waleed AL-Amoudi +6 more
wiley +1 more source
Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.
PLoS ONE, 2022 The selection of dialysate calcium concentration (D-Ca) is still controversial among chronic hemodialysis (HD) regimens. We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol ...
Kunitoshi Iseki +8 more
doaj +1 more source
Clinical Case Reports, Volume 13, Issue 12, December 2025.ABSTRACT Vitamin D‐dependent rickets type II (VDDR‐II) is a rare hereditary disorder caused by mutations in the vitamin D receptor gene, resulting in resistance to active vitamin D and impaired calcium absorption. We report a 2‐year and 6‐month‐old female toddler presenting with persistent rickets, delayed motor milestones, dental abnormalities, and ...
Abhisek Jha +8 more
wiley +1 more source
, 2023 This paper aims to discuss and compare 2 vitamin D derivatives available on the Polish market, alfacalcidol and calcitriol, in the context of their effectiveness and safety in endocrine patients.
Sewerynek, Ewa; Department of Endocrine Disorders and Bone Metabolism, Medical University of Lodz, Lodz, Poland +2 more
core +1 more source
Early bioprosthetic valve calcification with alfacalcidol supplementation
, 2015 We report a case of early bioprosthetic valve calcification in a 76 year-old woman who had received supplementation with alfacalcidol, an analogue of vitamin D, for 3 years after her initial valve replacement.
Fukui, Daisuke +6 more
core +2 more sources
IJU Case Reports, Volume 8, Issue 6, Page 567-570, November 2025.ABSTRACT Introduction Priapism is a persistent penile erection lasting > 4 h without sexual stimulation. Ischemic priapism requires urgent management. We report a recurrent ischemic priapism case post‐living‐donor kidney transplantation necessitating multiple interventions, including bilateral T‐shunt procedures.
Hiroto Kishino +9 more
wiley +1 more source